TD Cowen analyst Tara Bancroft has maintained their bullish stance on IRON stock, giving a Buy rating on November 3.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Tara Bancroft’s rating is based on several promising developments surrounding Disc Medicine’s key products and regulatory advancements. The company is on the verge of receiving approval for bitopertin, thanks to the FDA’s Commissioner’s National Priority Voucher (CNPV) designation, which significantly accelerates the review process. This regulatory milestone underscores the clinical significance of bitopertin and aligns with national health priorities, enhancing confidence in its market potential.
Furthermore, Disc Medicine’s pipeline shows strong potential with DISC-0974 and DISC-3405, which are expected to deliver positive clinical data. The upcoming data presentations at major conferences for MF anemia and NDD-CKD, along with potential expansions into new indications like SCD and IBD, provide additional growth avenues. These factors collectively support a positive outlook for Disc Medicine, justifying the Buy rating.
In another report released on November 3, Stifel Nicolaus also initiated coverage with a Buy rating on the stock with a $125.00 price target.